trial

Study Evaluating Vabicaserin in Subjects With Schizophrenia

NCTId NCT00563706
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 199 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2008-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
199 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-12
Primary completion
2008-06
Eligibility
MALE · 18 Years · 65 Years

Interventions & indications

Drugs
vabicaserinRisperidone

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

33 total
Little Rock, United StatesCerritos, United StatesEscondido, United StatesGarden Grove, United StatesGlendale, United StatesSan Diego, United StatesSan Diego, United StatesTorrance, United StatesWashington D.C., United StatesAventura, United StatesHollywood, United StatesKissimmee, United States

Linked catalysts

1
Study Evaluating Vabicaserin in Subjects With Schizophrenia — primary completion2008-06

Facts & assertions

4 sourced
Enrollment
199
Phase
PHASE2
Primary Completion Date
2008-06
Status
COMPLETED
relationships
The graph out of here
drug
vabicaserin
drug
Risperidone
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication